ANTX- An2 Therapeutics, Inc.
An2 Therapeutics, Inc. (ANTX) has 14 insiders with recent SEC Form 4 filings, including 18 buys and 4 sells. ANTX is classified in the Biotechnology industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 92.0K | $537.3K | - | |
| CFO | 82.3K | $480.6K | - | |
| Dir | 81.9K | $478.1K | - | |
| Other | 66.6K | $388.8K | - | |
| Dir | 59.1K | $345.2K | - |
Activity
Buys and sells only
Transactions
10 filings · page 2
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 28, 2025 | Fitzpatrick Margaret M | Director | Buy | 8,610 | $1.18 | $10,133.11 | New | 0.0% | +287.8% | |
| Jan 3, 2025 | Day Lucy55 | Chief Financial Officer | Sell | 2,957 | $1.34 | $3,965.34 | -8.3% | -1.4% | -21.8% | |
| Jan 3, 2025 | Chanda Sanjay55 | Chief Development Officer | Sell | 2,957 | $1.34 | $3,965.34 | -9.0% | -1.4% | -21.8% | |
| Jan 3, 2025 | Prior Stephen David60 | Chief Strategy Officer | Sell | 2,029 | $1.34 | $2,720.89 | -5.7% | -1.4% | -21.8% | |
| Jan 3, 2025 | Eizen Joshua M60 | See Remarks | Sell | 9,663 | $1.34 | $12,958.08 | -7.6% | -1.4% | -21.8% | |
| Dec 10, 2024 | Readnour Robin Shane52 | Director | Buy | 60,000 | $1.45 | $86,708.01 | +1.7% | -10.6% | -21.9% | |
| Nov 27, 2024 | Zakrzewski Joseph S55 | Director | Buy | 2,000 | $1.40 | $2,800.00 | +1.6% | -19.0% | -20.4% | |
| Nov 27, 2024 | Readnour Robin Shane52 | Director | Buy | 75,000 | $1.41 | $105,685.00 | +3.4% | -19.0% | -20.4% | |
| Nov 20, 2024 | Readnour Robin Shane52 | Director | Buy | 200,000 | $1.07 | $213,127.50 | +10.3% | -12.3% | -16.9% | |
| Nov 19, 2024 | Zakrzewski Joseph S55 | Director | Buy | 25,000 | $1.00 | $25,046.00 | +11.6% | +7.5% | +1.9% |